Status:
COMPLETED
Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly
Lead Sponsor:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Conditions:
Essential Hypertension
Eligibility:
All Genders
65+ years
Phase:
PHASE3
Brief Summary
To assess the efficacy of individually optimized doses of olmesartan medoxomil compared to losartan in elderly and very elderly patients with essential hypertension. The study hypothesis is non-inferi...
Eligibility Criteria
Inclusion
- Age 65 years or older
- Mean sitting diastolic BP = 100-114 mmHg and mean sitting systolic BP \>=150 mm HG
Exclusion
- Secondary hypertension
- Malignant hypertension
- Severe heart failure (NYHA III-IV)
- History or evidence of renal disease
- Recent history of myocardial infarction
- Hypersensitivity to study drugs
- History of drug or alcohol abuse
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT00751751
Start Date
June 1 2003
End Date
June 1 2005
Last Update
September 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Darmstadt, Germany